Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2026, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. “Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael.

Business Wire • 2 hours ago

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

Seeking Alpha • Oct 27, 2026

Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock

Bristol Myers Squibb TodayBMYBristol Myers Squibb$61.20 -0.28 (-0.45%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$42.52▼$68.64Dividend Yield4.12%P/E Ratio13.48Price Target$65.50Add to WatchlistGLP-1 agonists may have taken up most of the attention when it comes to game-changing drugs in the last couple of years, but the oncology landscape is heating up as well, and investors may see a transformation for some long-standing firms in the space.

MarketBeat • Oct 26, 2026

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Regulators in the U.S. extended the review period for Exelixis' request to approve a new cancer drug. However, the company's most important medicine is performing well and still has several years of growth before facing generic competition.

The Motley Fool • Oct 24, 2026

Exelixis Rises with Earnings on Tap

Shares of oncology company Exelixis, Inc. (EXEL) are higher by 177% since 2017.

FXEmpire • Oct 23, 2026

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2026

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Oct 16, 2026

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2026 financial results will be released on Thursday, October 29, 2026, after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please register using this link.

Business Wire • Oct 15, 2026

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 15, 2026

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of EXELIXIS, Inc. ( NASDAQ : EXEL)  breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.

PRNewsWire • Oct 13, 2026